| Literature DB >> 28250288 |
Jih-Ching Yeh1, Dan-Yuan Lo, Shao-Kuang Chang, Chi-Chung Chou, Hung-Chih Kuo.
Abstract
Escherichia coli (E. coli) is a zoonotic pathogen that often causes diarrhea, respiratory diseases or septicemia in animals. Fluoroquinolones are antimicrobial agents used to treat pathogenic E. coli infections. In this study, 1,221 E. coli strains were isolated between March, 2011 and February, 2014. The results of the antimicrobial susceptibility testing showed a high prevalence of quinolone resistance. The antimicrobial resistance rates of these E. coli isolates to nalidixic acid (NAL) were 72.0% in swine, 81.9% in chickens, 81.0% in turkeys, 64.0% in ducks and 73.2% in geese. Among these isolates, the positive rate for the plasmid-mediated quinolone resistance (PMQR) determinant was 14.8% (181/1,221); the detection rate for qnrS1 was the highest (10.2%), followed by aac(6')-Ib-cr (4.5%) and qnrB2 (0.3%). The quinolone-resistance determining regions (QRDRs) analysis for the PMQR-positive isolates showed that the strains with mutations at codon 83 or 87 in GyrA were resistant to NAL. To the best of our knowledge, this is the first report of occurrence of qnrB2, qnrS1 and aac(6')-Ib-cr genes and high frequency (56.4%; 102/181) of mutation in gyrA or parC among PMQR-positive E. coli strains derived from diseased animals in Taiwan.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28250288 PMCID: PMC5402195 DOI: 10.1292/jvms.16-0463
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Resistance percentage of isolates for five pre-selected antimicrobial agents
| Isolates ( | MIC range (mg/ | |||||
|---|---|---|---|---|---|---|
| NAL | FLU | ENR | CIP | MOX | ||
| Total (1,221) | ||||||
| MIC50 | 512 | 16 | 1 | 0.5 | 1 | |
| MIC90 | >1,024 | 1,024 | 128 | 64 | 64 | |
| R% | 76.4 | 74.3 | 50.6 | 42.3 | 51.3 | |
| Swine (583) | ||||||
| MIC50 | 512 | 16 | 1 | 0.5 | 1 | |
| MIC90 | >1,024 | 1,024 | 128 | 64 | 32 | |
| R% | 72.0a) | 71.2a) | 47.5a) | 39.8a) | 46.7a) | |
| Chicken (515) | ||||||
| MIC50 | >1,024 | 512 | 4 | 2 | 4 | |
| MIC90 | >1,024 | >1,024 | 128 | 64 | 64 | |
| R% | 81.9a,b) | 78.8a,b) | 55.2a,c) | 49.5a,c) | 57.3a–c) | |
| Turkey (42) | ||||||
| MIC50 | >1,024 | 32 | 1 | 0.5 | 1 | |
| MIC90 | >1,024 | 1,024 | 32 | 16 | 16 | |
| R% | 81.0 | 69.1 | 45.2 | 45.2 | 50.0 | |
| Duck (25) | ||||||
| MIC50 | 512 | 16 | 0.5 | 0.5 | 0.5 | |
| MIC90 | >1,024 | 1024 | 32 | 16 | 16 | |
| R% | 64.0b) | 64.0b) | 44.0 | 40.0 | 44.0b) | |
| Goose (56) | ||||||
| MIC50 | >1,024 | 16 | 1 | 0.5 | 1 | |
| MIC90 | >1,024 | 1024 | 32 | 16 | 16 | |
| R% | 73.2 | 73.2 | 48.2c) | 39.3c) | 48.2c) | |
NAL: Nalidixic acid, FLU: Flumequine, ENR: Enrofloxacin, CIP: Ciprofloxacin, MOX: Moxifloxacin. a) The results of MICs between swine and chicken were significant difference calculated by student t-test (P<0.05). b) The results of MICs between chicken and duck were significant difference calculated by student t-test (P<0.05). c) The results of MICs between chicken and goose were significant difference calculated by student t-test (P<0.05).
Distribution of PMQR determinants among E. coli isolates of different origin
| Swine (583) | 84 | 50 | 0 |
| Chicken (515) | 31 | 5 | 2 |
| Turkey (42) | 0 | 0 | 1 |
| Duck (25) | 1 | 0 | 0 |
| Goose (56) | 9 | 0 | 0 |
| Total | 125 | 55 | 3 |
Co-relationship of genotype and phenotype of 181 PMQR-positive E. coli isolates
| PMQR | QRDR | MIC (mg/ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gyr A-83 Ser | Gyr A-87 Asp | Par C-80 Ser | Par C-84 Glu | NAL | FLU | ENR | CIP | MOX | ||
| - | - | - | - | 73 | 4≥1,024 | ≤0.5–512 | ≤0.25–32 | ≤0.125–32 | ≤0.125–16 | |
| Ala | - | - | - | 3 | 64 | 16 | 2 | 1 | 4 | |
| Leu | - | - | - | 21 | 256≥1,024 | 8–1,024 | 0.5–64 | 0.25–32 | 0.5–128 | |
| Leu | - | Arg | - | 1 | >1,024 | 512 | 4 | 4 | 4 | |
| Leu | - | Ile | - | 1 | >1,024 | 512 | 32 | 32 | 64 | |
| Leu | Asn | Ile | - | 24 | >1,024 | 1,024≥1,024 | 16–128 | 16–64 | 16–256 | |
| - | - | - | - | 3 | 16 | 4–16 | 0.5–1 | 0.25 | 1–2 | |
| - | - | - | - | 3 | 4–16 | ≤0.5–2 | ≤0.25 | ≤0.125 | ≤0.125–0.25 | |
| - | Gly | - | - | 2 | 128 | 4–8 | ≤0.25 | 0.25 | ≤0.125–0.25 | |
| Ala | - | - | - | 2 | 128–256 | 16 | 0.5 | 1 | 0.5 | |
| Leu | - | Ile | - | 1 | >1,024 | 1,024 | 2 | 4 | 1 | |
| Leu | - | Arg | - | 3 | >1,024 | 512–1,024 | 4–16 | 16 | 2–8 | |
| Leu | Asn | Ile | - | 26 | >1,024 | 512≥1,024 | 32≥512 | 32≥256 | 16–256 | |
| Leu | Tyr | Ile | - | 2 | >1,024 | 1,024≥1,024 | 64–256 | 64–256 | 32–256 | |
| Leu | Asn | Ile | Ala | 7 | >1,024 | 512≥1,024 | 64–128 | 64 | 32 | |
| Leu | Asn | Ile | Gly | 7 | >1,024 | 1,024≥1,024 | 128≥512 | 64–256 | 32–256 | |
| Leu | Asn | Ile | - | 2 | >1,024 | 1,024 | 16–128 | 16–128 | 16–128 | |
NAL: Nalidixic acid, FLU: Flumequine, ENR: Enrofloxacin, CIP: Ciprofloxacin, MOX: Moxifloxacin.